Enhabit, Inc. (NYSE:EHAB) Director Acquires $82,400.00 in Stock

Enhabit, Inc. (NYSE:EHAB - Get Free Report) Director Jeffrey Bolton purchased 10,000 shares of Enhabit stock in a transaction dated Friday, May 10th. The shares were bought at an average price of $8.24 per share, with a total value of $82,400.00. Following the completion of the transaction, the director now owns 42,299 shares in the company, valued at approximately $348,543.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Enhabit Trading Up 0.5 %

Shares of NYSE:EHAB traded up $0.04 during trading on Friday, reaching $8.33. 1,601,494 shares of the stock were exchanged, compared to its average volume of 319,834. Enhabit, Inc. has a 12-month low of $7.12 and a 12-month high of $14.59. The firm's 50-day moving average price is $10.36 and its 200 day moving average price is $10.02. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.76.

Enhabit (NYSE:EHAB - Get Free Report) last posted its earnings results on Wednesday, March 6th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.01. Enhabit had a negative net margin of 7.69% and a positive return on equity of 1.55%. The business had revenue of $260.60 million for the quarter, compared to analyst estimates of $260.30 million. During the same quarter in the previous year, the business posted $0.32 EPS. Equities analysts forecast that Enhabit, Inc. will post 0.24 earnings per share for the current year.

Analyst Ratings Changes

EHAB has been the topic of several recent research reports. UBS Group upgraded shares of Enhabit from a "sell" rating to a "neutral" rating and set a $9.50 price objective on the stock in a research report on Thursday, March 7th. Oppenheimer restated a "market perform" rating on shares of Enhabit in a research report on Thursday, March 7th. Finally, Jefferies Financial Group lowered Enhabit from a "buy" rating to a "hold" rating and decreased their price target for the stock from $14.00 to $8.75 in a research note on Thursday. Two investment analysts have rated the stock with a sell rating and five have issued a hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $11.21.

Hedge Funds Weigh In On Enhabit

Hedge funds and other institutional investors have recently bought and sold shares of the stock. JANA Partners Management LP acquired a new stake in Enhabit during the 3rd quarter valued at $20,532,000. UBS Group AG grew its stake in shares of Enhabit by 7,973.5% during the third quarter. UBS Group AG now owns 1,633,751 shares of the company's stock valued at $18,380,000 after acquiring an additional 1,613,515 shares in the last quarter. Ancora Advisors LLC increased its position in shares of Enhabit by 414.5% during the third quarter. Ancora Advisors LLC now owns 1,705,788 shares of the company's stock worth $19,190,000 after acquiring an additional 1,374,231 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in shares of Enhabit by 12,146.2% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 244,924 shares of the company's stock worth $2,543,000 after acquiring an additional 242,924 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Enhabit by 25.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 966,515 shares of the company's stock valued at $10,003,000 after purchasing an additional 193,675 shares during the last quarter.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.